Company / Current Liabilities
Jade Biosciences, Inc. Current Liabilities History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$3.8M
FY2024
5-year range
$1.8M / $17.6M
FY2020-FY2024
Trend
-78.3%
vs FY2023
Sector context
#212 of 214
Health Care
What the data says
Among 214 Health Care companies, Jade Biosciences, Inc. is in the top 1% for current liabilities. Improved from $8M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2024 with a 3-year CAGR of +14.5%.
Improved from $8M to $4M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +14.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 214This company $3.8M Sector average $1.6B
▼
-99.8% below sector average
Key checks
Key Insights
- 3-year CAGR of +14.5%, indicating consistent growth.
- In FY2024, current liabilities decreased 78.3% year-over-year.
- Ranks #212 out of 214 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.8M | -78.3% |
| FY2023 | $17.6M | +126.6% |
| FY2022 | $7.8M | +205.2% |
| FY2021 | $2.5M | +43.7% |
| FY2020 | $1.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026